These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15114066)

  • 1. Taking our medicine: who should pay for what?
    Deber R
    Healthc Pap; 2004; 4(3):27-8; discussion 68-72. PubMed ID: 15114066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-Romanow pharmacare: last-dollar first...first-dollar lost?
    Morgan SG; Willison DJ
    Healthc Pap; 2004; 4(3):10-20. PubMed ID: 15114064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stop the merry-go-round.
    Lexchin J
    Healthc Pap; 2004; 4(3):29-34; discussion 68-72. PubMed ID: 15114067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognize the role of employers.
    French M
    Healthc Pap; 2004; 4(3):46-50; discussion 68-72. PubMed ID: 15114069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policy choices for pharmacare; the need to examine benefit design, medication management strategies and evaluation.
    Sketris IS; Brown MG; Murphy AL
    Healthc Pap; 2004; 4(3):36-45; discussion 68-72. PubMed ID: 15114068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States.
    Pomey MP; Forest PG; Palley HA; Martin E
    Milbank Q; 2007 Sep; 85(3):469-98. PubMed ID: 17718665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
    Coombes ME; Morgan SG; Barer ML; Pagliccia N
    Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hard decisions about fundamental values.
    Laupacis A
    Healthc Pap; 2004; 4(3):60-6; discussion 68-72. PubMed ID: 15114071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the effects of Quebec's private-public drug insurance system.
    Morgan SG; Gagnon MA; Charbonneau M; Vadeboncoeur A
    CMAJ; 2017 Oct; 189(40):E1259-E1263. PubMed ID: 29018085
    [No Abstract]   [Full Text] [Related]  

  • 10. To build a wooden horse...integrating drugs into the public health system.
    Forest PG
    Healthc Pap; 2004; 4(3):22-6; discussion 68-72. PubMed ID: 15114065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
    Daw JR; Morgan SG
    Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dilemmas in regulation of the market for pharmaceuticals.
    Maynard A; Bloor K
    Health Aff (Millwood); 2003; 22(3):31-41. PubMed ID: 12757269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National pharmacare: a dog's tale.
    Anis AH
    CMAJ; 2004 Sep; 171(6):565-6. PubMed ID: 15367455
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
    Brandt J; Shearer B; Morgan SG
    J Pharm Policy Pract; 2018; 11():28. PubMed ID: 30443371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug coverage insurance as a novel element of private health insurance in Poland.
    Czerw A; Religioni U
    Acta Pol Pharm; 2013; 70(4):763-7. PubMed ID: 23923401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal Pharmacare in Canada: A Prescription for Equity in Healthcare.
    Hajizadeh M; Edmonds S
    Int J Health Policy Manag; 2020 Mar; 9(3):91-95. PubMed ID: 32202091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription drug benefits for seniors and public/private collaboration.
    Brekke M
    Beginnings; 2002; 22(3):11. PubMed ID: 12046112
    [No Abstract]   [Full Text] [Related]  

  • 18. Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program.
    Sorin M; Franco EL; Quesnel-Vallée A
    Curr Oncol; 2019 Aug; 26(4):266-269. PubMed ID: 31548806
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whither seniors' pharmacare: lessons from (and for) Canada.
    Morgan SG; Barer ML; Agnew JD
    Health Aff (Millwood); 2003; 22(3):49-59. PubMed ID: 12757272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.